comparemela.com

Latest Breaking News On - Prnewswire cantargia - Page 1 : comparemela.com

Cantargia AB: Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for

Region flamandeDavid libergVan cutsemDominique tersagoEric van cutsemPrnewswire cantargiaUniversity hospitals gasthuisbergVp researchUniversity of warsawBelgian foundationNasdaq stockholmDivision headDigestive oncologyEric vanMedical universityProf van cutsem

Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today.

Region flamandeVan cutsemEric van cutsemPhderic van cutsemDominique tersagoDavid libergPrnewswire cantargiaUniversity hospitals gasthuisbergVp researchBelgian foundationUniversity of warsawNasdaq stockholmDivision headDigestive oncologyEric vanMedical university

Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today.

Prnewswire cantargiaSpanish breast cancer groupNasdaq stockholm

Cantargia AB: Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been

Dennis riedlPrnewswire cantargiaClinical research excluding trialsNasdaq stockholmClinical research excludingTherapeutic benefitMonday aprWednesday apr

Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today.

Prnewswire cantargiaClinical research excluding trialssessionNasdaq stockholmTherapeutic benefitMonday aprWednesday apr

vimarsana © 2020. All Rights Reserved.